This study evaluated Zonisamide Weight Loss in Obese Adults. Among 51 randomized subjects, seven percent of the responders had lost at least 10 percent of their body weight, while none of the placebo-treated groups achieved this level. At the end of the trial, a total of 5.5 kg of excess body fat had been lost, which was statistically significant compared to the placebo. In addition, zonisamide was well tolerated by participants. In addition, the drug reduced cravings for sweets.
However, Zonisamide Weight Loss in Obese Adults may not be suitable for all patients. While zonisamide inhibits carbonic anhydrase, it has also been shown to alter taste. Researchers have not confirmed this relationship between zonisamide and obesity, but this effect does have some positive impact on weight loss. This drug may be the solution to your problem of obesity. As an oral dietary supplement, Zofran is an excellent choice for people who are trying to lose weight.
With Zonisamide Weight Loss in Obese Adults study, weight loss was observed in 76% of the patients. The study participants were given hypocaloric diets for up to eight weeks after starting zonisamide treatment. Some of the side effects included nausea/vomiting, fatigue, and gastrointestinal problems. Nonetheless, overall weight loss was observed in all groups. Although the treatment is not yet approved for treating severe underlying conditions, zonisamide is a viable option for patients with weight-loss concerns.
With Zonisamide Weight Loss in Obese Adults study, participants took either 200 mg or 400 mg of zonisamide daily for eight weeks. The study results showed that zonisamide did indeed reduce body weight, and the results were consistent with the expected outcomes. In addition, the weight change was higher in the full-dose compliant group. In addition, further analysis showed that zonisamide induced more weight loss than the placebo.
The pharmacologic treatment of zonisamide is well tolerated in healthy individuals. The trial showed that zonisamide was effective in reducing weight by up to nine percent among the randomized group. At the end of the study, the medication significantly enhanced the loss of 5% of body weight. Despite the adverse effects associated with zonisamide, it is the first choice for obese patients. The drug is an anti-epileptic drug, which has high incidences of side effects.
The results of the study were similar between the zonisamide and placebo groups. At baseline, the average BMI of the participants was 38 kg and the average BMI was 42.4. After 16 weeks, zonisamide treatment reduced weight by 4.8 kg in the paroxetine-treated group. The results showed that zonisamide is a promising candidate for weight loss. The study’s findings were published in a scholarly journal in the Journal of Applied Psychology.
In the current study, the pharmacological treatment zonisamide induced a 5.7 kg decrease in mean body weight in 16 weeks. The hazard ratio of zonisamide was 0.5. After the study, a randomized trial would yield a more definitive conclusion. The outcome of the trial would be more effective if a large number of patients lose weight than those who lose only a few kilograms.